We are live on ! Find out more
KNTE

Kinnate Biopharma Inc. Common Stock
KNTE

Delisted

KNTE was delisted on the 2nd of April, 2024.

Back to rankings

73 hedge funds and large institutions have $493M invested in Kinnate Biopharma Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 27 increasing their positions, 13 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

108% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 13

6% more capital invested

Capital invested by funds: $465M → $493M (+$27.7M)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

7% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 15

4% less funds holding

Funds holding: 76 → 73 (-3)

Holders
73
Holders Change
-3
Holders Change %
-3.95%
% of All Funds
1.23%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
14
Increased
27
Reduced
13
Closed
15
Calls
$615K
Puts
–
Net Calls
+$615K
Net Calls Change
+$97K

Top Buyers

Rank Fund Capital Flow
1
LCM
Lynx1 Capital Management
Puerto Rico
+$9.14M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$6.97M
3
RSCM
Rock Springs Capital Management
Maryland
+$2.55M
4
BlackRock
BlackRock
New York
+$2.27M
5
NHAS
Novo Holdings A/S
Denmark
+$1.78M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$6.85M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$4.28M
3
HF
HRT Financial
New York
-$1.03M
4
Swiss National Bank
Swiss National Bank
Switzerland
-$270K
5
Two Sigma Investments
Two Sigma Investments
New York
-$259K
Name Holding Trade Value Shares
Change 		Change in
Stake
FCMI
1
Foresite Capital Management IV
California
$122M – – –
RCM
2
RA Capital Management
Massachusetts
$53.8M – – –
NI
3
Nextech Invest
Switzerland
$37.9M – – –
VVA
4
Vida Ventures Advisors
Massachusetts
$34.6M – – –
BlackRock
5
BlackRock
New York
$29M +$2.27M +244,320 +12%
Fidelity Investments
6
Fidelity Investments
Massachusetts
$27.7M +$6.97M +749,012 +52%
BC
7
Boxer Capital
California
$23.3M – – –
Viking Global Investors
8
Viking Global Investors
Connecticut
$23M – – –
LCM
9
Lynx1 Capital Management
Puerto Rico
$21.1M +$9.14M +982,169 +142%
Citadel Advisors
10
Citadel Advisors
Florida
$14.2M -$52.7K -5,665 -0.5%
Vanguard Group
11
Vanguard Group
Pennsylvania
$12.6M -$4.28M -459,557 -32%
FCMV
12
Foresite Capital Management V
California
$11M – – –
NHAS
13
Novo Holdings A/S
Denmark
$10.3M +$1.78M +191,471 +31%
RSCM
14
Rock Springs Capital Management
Maryland
$7.8M +$2.55M +274,238 +80%
HMC
15
Harvard Management Company
Massachusetts
$6.28M – – –
State Street
16
State Street
Massachusetts
$5.7M +$271K +29,124 +7%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$5.18M +$422K +45,381 +12%
American Century Companies
18
American Century Companies
Missouri
$4.04M +$3.98K +428 +0.1%
Federated Hermes
19
Federated Hermes
Pennsylvania
$3.88M – – –
FCOMV
20
Foresite Capital Opportunity Management V
California
$3.68M – – –
WP
21
Woodline Partners
California
$3.28M – – –
DM
22
Deerfield Management
New York
$3.15M -$6.85M -735,568 -75%
Northern Trust
23
Northern Trust
Illinois
$2.85M +$165K +17,769 +9%
DCM
24
DAFNA Capital Management
California
$2.83M +$710K +76,300 +52%
Goldman Sachs
25
Goldman Sachs
New York
$2.66M +$1.33M +142,804 +210%
1
2 3 4

KNTE Hedge Fund Activity: Q2 2022 in Review

73 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Kinnate Biopharma Inc. Common Stock (KNTE) for Q2 2022, worth a combined $493M — up 6% from $465M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of KNTE and 14 opened new positions — a net loss of 1 holder — while 13 trimmed existing stakes and 27 added.

The largest buyer was Lynx1 Capital Management, adding an estimated $9.14M. The largest seller was Deerfield Management, cutting an estimated $6.85M.

  • 73 institutional investors held Kinnate Biopharma Inc. Common Stock (KNTE) as of Q2 2022, down from 76 in Q1 2022.
  • Funds reported $493M of Kinnate Biopharma Inc. Common Stock stock for Q2 2022, up 6% quarter-over-quarter.
  • 14 funds opened new Kinnate Biopharma Inc. Common Stock positions in Q2 2022 and 15 closed out, a net change of -1 holder.
  • The largest Kinnate Biopharma Inc. Common Stock buyer in Q2 2022 was Lynx1 Capital Management, an estimated $9.14M added.
  • The largest Kinnate Biopharma Inc. Common Stock seller in Q2 2022 was Deerfield Management, an estimated $6.85M sold.

Based on aggregated 13F filings for Q2 2022.